

Original Article

Evaluation of the effect of bupropion on personality factors in depressed patients

Mohamad Nadi Sakhvidi*, Fatemeh Hosseini, Samaneh Mahmoudi

Department of Psychiatry, Shahid Sadoughi University of Medical Sciences, Yazd, IR Iran

Correspondence: Mohamad Nadi Sakhvidi, Department of Psychiatry, Shahid Sadoughi University of Medical Sciences, Yazd, IR Iran

ABSTRACT

Introduction: 10 to 20 percent of the population and about half of outpatient and hospitalized patients suffer from personality disorder. Drug therapy is one of the effective therapies for personality disorders. The objective of this study was to evaluate the relationship between the use of drugs and personality factors, which could be helpful in the use of more effective drugs in the treatment of personality disorders. This study evaluated the effect of bupropion, a widely-used drug in treatment of depression, on personality factors. Methodology: This is a randomized clinical trial study conducted on patients with major depression who referred to medical University Clinics in Yazd. A total of 30 depressed patients were included in this research. Then, they received Beck Inventory and 125 TCI test. The patients were followed-up in the clinic after 6 weeks of treatment. After being interviewed and examined by a psychiatrist, the patients received the TCI and Beck tests again. Finally, the results of each subject were submitted to the statistics consultant to analyze the data. Results: Based on Paired Sample Test and p-value test, there is a significant difference between the mean scores of Beck before and after the treatment and bupropion. In addition, the difference between mean scores of factors of novelty-seeking and reward dependence and self-directedness, cooperativeness, and self-transcendence before and after the treatment and bupropion are significant. Conclusion: Based on this study, treatment of depression with bupropion causes changes in personality factors. The results of this research can be helpful in treatment of patients with personality disorders. However, further investigations are required to examine the effects of other psychotropic drugs on the treatment of personality disorders, such as antipsychotics and other antidepressants.

Keywords: Bupropion, personality factors, vulnerability, novelty-seeking, persistence, depressed patients.

Introduction

The personality refers to all the features making distinction between continuously evolving living creatures and a completely predictable machine object. By recognizing the personality of people, we can gain adequate knowledge on behavior and relationships among the people [1]. Recognizing the personality and its disorders differentiates it fundamentally from other branches of medicine. These disorders are very common

Access this article online	
Website: www.japer.in	E-ISSN: 2249-3379

How to cite this article: Mohamad Nadi Sakhvidi, Fatemeh Hosseini, Samaneh Mahmoudi. Evaluation of the effect of bupropion on personality factors in depressed patients. J Adv Pharm Edu Res 2020; 10(82):129-134. Source of Support: Nil, Conflict of Interest: None declared.

in current community. Almost 10 to 20 percent of the

community and about half of outpatient and hospitalized patients are afflicted with personality disorder. The importance of investigating the basic patterns of human behavior has been always emphasized and many explorations have been made in this path to achieve the main dimensions of personality. Personality disorder is often associated with other clinical syndromes such as depression. In addition, disorders such as mood disorder and anxiety disorder affect personality dimensions, but much of the personality is not related to mood and anxiety [2]. Enhancing the quality of life of psychiatric patients largely depends on positive developments in their personality. Psychiatric treatment should be directed towards improvement of mental health of the individual and reducing the negative symptoms of mental disorder [3,4].

The personality can be divided into three parts of Temperament, Character, and Psyche. The four main attributes of the temperament include novelty seeking (NS), harm avoidance (HA), persistence (P), and reward dependence (RD), and three attributes of character include self-directedness (SD), cooperativeness (C) and self-transcendence (ST) [1].

This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-Non Commercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.

Temperament components have a neurobiological basis and are inherited and the components of the character reflect the cultural and social education. All components of temperament are specific to the activity of the neurotransmitter system ^[5]. The main neuromodulator of the vulnerability is the Gaba neurotransmitter and serotonin, and the neuromodulator of novelty seeking is dopamine. The neuromodulator of reward dependence is norepinephrine and serotonin and the neuromodulator of persistence is glutamate and serotonin.

One of the effective treatments for personality disorders is drug therapy. Psychiatric drugs also affect the components of the personality by leaving effects on these neurotransmitters [1, 6]. The other treatment used in this regard is psychotherapy [7]. Given the inaccessibility of psychotherapy and its high cost, drug therapy has always been considered seriously in treatment of these patients [8, 9]. Tomita et al. (2015) examined TCI changes with paroxetine treatment study in a study conducted on 48 patients with major depression. The TCI and Montgomery Asberg depression rating scale were performed on week 0 and 6and patients were divided into three groups of responders and non-responders and early responders 6 weeks after treatment with paroxetine. Then, the TCI changes in these groups before and after treatment were compared. In the respondent group and early respondent group, TCI criteria did not change [10].

In a study conducted in 2010 on 98 patients with major depression, Kampman et al. examined the relationship between response to therapy and the temperament criteria in TCI. Six weeks before and after treatment with SSRI, patients received TCI questionnaire. HA was significantly higher before and after treatment compared to the normal population, and patients, especially men, had higher RD. Finally, it was found that HA was associated with response to treatment [11]. In 2004, Joyce et al examined the personality of patients with atypical depression. A total of 195 outpatient depressed patients were treated with nortriptyline and fluoxetine, which 16 of them with DSM 4 diagnosis received atypical depression, and then, personality types in people with and without atypical depression were compared.

In atypical depression, fluoxetine was more effective than nortriptyline, and atypical group showed more cohesion and lower persistence and more expected anxiety than other group [12]. In 2002, Hirano et al studied 108 depressed patients. First, their depression was evaluated by using Hamilton Test. Then, they underwent TCI test before and 16 weeks after antidepressant treatment. They found that the rate of depression had a direct relationship with the HA score, with a negative correlation with C and SD scores. These three criteria were changed in respondent group during the treatment and these changes were associated with change in intensity of depression [13]. The objective of this research was to evaluate the relationship between the use of drugs and personality factors, which could be helpful in the use of more effective drugs in the treatment of personality disorders. Hence, this research was

conducted to evaluate the effect of the widely used drug of bupropion depression on personality factors.

Methodology

Research population and characteristics of subjects:

Sampling in this research was performed from September 2015 to September 2016 in patients with major depression referred to Shahid Sadoughi University Clinics in Yazd.

The research inclusion criteria include:

1-People aged above 18 years 2. Patients with major depression.

Research exclusion criteria include:

1-a psychiatric disorder other than depression, 2. Types of seasonal depression. 3. Sexual dysfunction at considerable level.
4. Patient undergoing treatment (passing 6 months of the last treatment, if treated before).

Research method

This study was conducted using randomized clinical trial.

Sampling method and sample size determination:

Convenient sampling method was used in this research. Sampling was performed on those referred to Shahid Sadoughi University Clinics. Given the significance level of 5% and the test power of 80%, and considering the standard deviation of scores of 7 domains of TCI (3.5) and to achieve the minimum significant difference in the mean score of HA in each group, sample size was determined to be 30 people. The formula to calculate sample number required for this research is as follows:

$$N = \frac{(z \alpha/2 + Z\beta)^2 \times 2S^2}{(X_1 - X_2)^2}$$

Variables and tools for data collection and analysis:

In this research, Beck inventory 2 was used to evaluate depression and 125-item TCI questionnaire was used to evaluate the personality factors. The personal information of the participants was recorded in this research.

TCI test

Temperament and Character Inventory is a psychological test used for evaluation of personality and it has been developed by Cloninger based on the personality bio-social model. TCI has been designed based on self-report. This test assesses the four dimensions of temperament of novelty seeking, harm avoidance, reward dependence, persistence, and three dimensions of character, including cooperativeness, self-directedness and self-transcendence. The questionnaire used in this research included 125 questions, answered based on two

options of true and false. This test has good validity and reliability in Iranian population [3, 14].

Beck Inventory

Beck-Depression Inventory-2 is a depression screening test focusing on cognitive, behavioral, and physical symptoms. Beck Test is able to assess the severity of depression and is sensitive to change, so it is used to assess response to treatment. The reliability coefficient of the test is 78 and its validity is 70-90.

Procedure

In this research, patients with major depression referred to Shahid Sadoughi University Clinics of Yazd were examined. First, major depression was diagnosed clinically by the psychiatrist based on the DSM4-TR diagnostic criteria. After initial evaluation and ensuring the research inclusion criteria, the necessary explanations were provided for the patients on the research project and their written consent to participate in the research was taken from them.

Then, they received Beck inventory and the 125 TCI Test. Then, based on the order of the list of random numbers table prepared by the statistics consultant to achieve the desired homogeneity among the subjects and the type of the selected group (identified in numbers of 1 and 2), 30 People were included into bupropion-treated group. The patients were followed-up 6 weeks after treatment in clinic, so that patients underwent gain TCI and Beck tests after being interviewed and examined by a psychiatrist. Finally, results of each person were submitted to the statistics consultant to analyze the data.

Limitations and executive and moral problems of research

One of the most important problems in this research was the large number of questions of the inventory, led to patients' unwillingness to cooperate and lack of giving adequate response owing to requiring much time to complete it. Non-tolerance of drug by some of the samples or side effects led to the discontinuation of treatment by patients as well as the lack of follow-up of treatment by some patients led to their exclusion from study were some of the limitations of the study.

Results

In this research, a total of 74 patients over the age of 18 with major depression referred to Yazd Shahid Sadoughi University Clinics since September 2015 to September 2016 who did not meet the exclusion criteria of research and were willing to participate in the study were examined. All patients were interviewed and examined clinically by a Beck Inventory and TCI test. Then, 36 patients were treated with bupropion using a random number table.

Finally, 14 patients were excluded from the study. Five patients had to replace the drug owing to drug side effects and non-tolerance, and 9 patients did not referred to follow up the treatment and they were excluded from the study. Finally, intervention was performed on 30 patients receiving

bupropion, and after 6 weeks, they were re-examined with Beck Inventory and TCI test. Finally, their data were analyzed. The results showed that the mean age of the bupropion-receiving group was 38.57 years.

In this research, 14 male and 16 female patients received bupropion. In the bupropion group, 9 subjects had elementary, 4 subjects had secondary, 7 subjects had high school, and 5 subjects had associate and 2 subjects had bachelor, and 3 had education higher than bachelor (Table 1).

Table 1: Determination and comparison of frequency distribution of gender and educational level in the study group

	variable	Bupropion group
gender	male	14
	female	16
	total	30
Education level	Elementary	9
	secondary	4
	High school	7
	associate	5
	bachelor	2
	higher	3
	total	30

The mean score before treatment in the bupropion-receiving group was 33.73. In addition, the mean Beck Inventory score after treatment in the bupropion-receiving group was 19.33 (Table 2).

Table 2: Determination and comparison of mean score of Beck test before and after treatment in two study

ł		
Variable	group	n
Beck test before drug use	bupropion	30
Beck test after drug use	bupropion	30

In the bupropion-treated group, the mean score of bupropion was 33.73 before treatment and it was 19.33 after treatment. Using paired samples and p-value = .000, the mean scores of Beck test before and after treatment were significant. The mean scores of NS before and after treatment in the bupropion group was 8.20 and 14.23, respectively, which showed a significant difference (P-value = .000).

The mean score of HA before and after treatment in bupropion group was 14.03 and 13.60 respectively, and there was no significant difference in this regard P-value = 0.248). The mean score of RD was 8.40 before treatment with bupropion and it was 10.50 after treatment, which it was significant with P-value = 0.000. The mean P score before and after treatment with

bupropion was 3.13 and 3.57, respectively, and there was no significant difference between them (P-value = 0.073).

In the bupropion group, the mean SD score was 8.00 before treatment and it was 11.70 after treatment, which this difference was significant (P value = .000). The mean score of CO was 15.47 before treatment and it was 16.57 after treatment, which this difference significant with P-value = 0.019. The mean score of ST was 10.47 before treatment with bupropion and it was 11.43 after treatment. The standard deviation before and after treatment with bupropion was 2.813 and 2.223, respectively, and this difference was significant with P-value = 0.022 (Table 3).

Table 3: Determination and comparison of mean scores of Beck and TCI tests before and after treatment with

Variable mean SD p-value Beck before drug use 33.73 7.746 .000 Beck after drug use 19.33 11.360 .000 Novelty-seeking before drug use 8.20 2.709 .000 Novelty-seeking after drug use 14.23 3.104 .000 Harm avoidance before drug use 14.03 3.113 .248 Harm avoidance after drug use 13.60 3.058 .248 reward dependence after drug use 8.40 2.222 .000 reward dependence after drug use 3.13 1.634 .073 Persistence before drug use 3.57 1.305 .073 Self-directedness before drug use 8.00 4.119 .000 Self-directedness after drug use 11.70 4.244 .000 Cooperativeness before drug use 15.47 2.556 .019 Cooperativeness after drug use 16.57 2.837 .019 Self-transcendence before drug use 10.47 2.813 .022	1	bupropion		
Novelty-seeking before drug use 19.33 11.360 .000	Variable	mean	SD	p-value
Novelty-seeking before drug use 8.20 2.709 .000	Beck before drug use	33.73	7.746	000
Array use 8.20 2.709 .000	Beck after drug use	19.33	11.360	.000
Array use 8.20 2.709 .000	Novelty-seeking before			
Novelty-seeking after drug use 14.23 3.104 .000	, .	8.20	2.709	
Harm avoidance before drug use 14.03 3.113 .248 Harm avoidance after drug 13.60 3.058 .248 Item avoidance after drug 13.60 3.058 .248 Item avoidance after drug 13.60 3.058 .248 Item avoidance after drug use 8.40 2.222 .000 Item avoidance after 10.50 2.301 .000 Item avoidance after 10.50 2.301 .000 Item avoidance after 10.50 2.301 .000 Item avoidance after 10.50 3.058 .000 Item avoidance after 10.47 2.813 .0022 Item avoidance after 10.47 2.813 .022 Item avoidance after 10.47 2.813 .				.000
drug use 14.03 3.113 .248 Harm avoidance after drug 13.60 3.058 .248 reward dependence before drug use 8.40 2.222 .000 reward dependence after drug use 10.50 2.301 .000 Persistence before drug use 3.13 1.634 .073 Self-directedness before drug use 8.00 4.119 .000 Self-directedness after drug 11.70 4.244 .000 Cooperativeness before drug use 15.47 2.556 .019 Cooperativeness after drug 16.57 2.837 .019 Self-transcendence before drug use 10.47 2.813 .022 Self-transcendence after 11.43 2.223 .022				
Harm avoidance after drug use 13.60 3.058 .248	Harm avoidance before			
Harm avoidance after drug use 13.60 3.058 .248	drug use	14.03	3.113	
reward dependence before drug use 8.40 2.222 reward dependence after drug use 10.50 2.301 Persistence before drug use 3.13 1.634 Persistence after drug use 3.57 1.305 Self-directedness before drug use 8.00 4.119 Self-directedness after drug 11.70 4.244 use 15.47 2.556 Cooperativeness after drug 16.57 2.837 use Self-transcendence before drug use 10.47 2.813 Self-transcendence after 11.43 2.223	· ·	13.60	3.058	.248
drug use 8.40 2.222 .000 reward dependence after drug use 10.50 2.301 .000 Persistence before drug use 3.13 1.634 .073 Persistence after drug use 3.57 1.305 .073 Self-directedness before drug use 8.00 4.119 .000 Self-directedness after drug use 11.70 4.244 .000 Cooperativeness before drug use 15.47 2.556 .019 Cooperativeness after drug use 16.57 2.837 .019 Self-transcendence before drug use 10.47 2.813 .022 Self-transcendence after 11.43 2.223 .022	C			
reward dependence after drug use 10.50 2.301 .000 Persistence before drug use 3.13 1.634 .073 Persistence after drug use 3.57 1.305 .073 Self-directedness before drug use 8.00 4.119 .000 Self-directedness after drug use 11.70 4.244 .000 Cooperativeness before drug use 15.47 2.556 .019 Cooperativeness after drug use 16.57 2.837 .019 Self-transcendence before drug use 10.47 2.813 .022 Self-transcendence after 11.43 2.223 .022	reward dependence before			
reward dependence after drug use 10.50 2.301 Persistence before drug use 3.13 1.634 .073 Self-directedness before drug use 8.00 4.119 .000 Self-directedness after drug use 11.70 4.244 .000 Cooperativeness before drug use 15.47 2.556 .019 Cooperativeness after drug use 16.57 2.837 .019 Self-transcendence before drug use 10.47 2.813 .022 Self-transcendence after 11.43 2.223 .022	drug use	8.40	2.222	000
Persistence before drug use 3.13 1.634 .073 Self-directedness before drug use 8.00 4.119 Self-directedness after drug 11.70 4.244 .000 Cooperativeness before drug use 15.47 2.556 Cooperativeness after drug 16.57 2.837 .019 use Self-transcendence before drug use 10.47 2.813 .022 Self-transcendence after 11.43 2.223	reward dependence after	10.50	2.301	.000
Persistence after drug use 3.57 1.305 Self-directedness before drug use 8.00 4.119 Self-directedness after drug 11.70 4.244 use Cooperativeness before drug use 15.47 2.556 Cooperativeness after drug 16.57 2.837 use Self-transcendence before drug use 10.47 2.813 Self-transcendence after 11.43 2.223	drug use			
Self-directedness before drug use 8.00 4.119 .000	Persistence before drug use	3.13	1.634	073
drug use 8.00 4.119 .000	Persistence after drug use	3.57	1.305	.073
Self-directedness after drug use Cooperativeness before drug use 15.47 2.556 Cooperativeness after drug 16.57 2.837 use Self-transcendence before drug use 10.47 2.813 Self-transcendence after 11.43 2.223	Self-directedness before			
Cooperativeness before drug use 11.70 4.244 Cooperativeness before drug use 15.47 Cooperativeness after drug use 16.57 2.837 use Self-transcendence before drug use 10.47 2.813 Self-transcendence after 11.43 2.223	drug use	8.00	4.119	000
Cooperativeness before drug use 15.47 2.556 Cooperativeness after drug 16.57 2.837 use Self-transcendence before drug use 10.47 2.813 Self-transcendence after 11.43 2.223	Self-directedness after drug	11.70	4.244	.000
drug use 15.47 2.556 Cooperativeness after drug 16.57 2.837 use Self-transcendence before drug use 10.47 2.813 Self-transcendence after 11.43 2.223	use			
drug use 15.47 2.556 Cooperativeness after drug 16.57 2.837 use Self-transcendence before drug use 10.47 2.813 Self-transcendence after 11.43 2.223	Cooperativeness before			
Cooperativeness after drug use 16.57 2.837 .019 Self-transcendence before drug use 10.47 2.813 .022 Self-transcendence after 11.43 2.223	•	15.47	2.556	
self-transcendence before drug use 10.47 2.813 .022 Self-transcendence after 11.43 2.223	e e	16.57		.019
drug use 10.47 2.813 Self-transcendence after 11.43 2.223				
Self-transcendence after 11.43 2.223 .022	Self-transcendence before			
Self-transcendence after 11.43 2.223	drug use	10.47	2.813	022
drug use	Self-transcendence after	11.43	2.223	.022
	drug use			

According to the above table, the Paired Sample Test and p-values presented, there is a significant difference between the mean scores before and after treatment with bupropion. Moreover, the difference between mean scores of novelty-seeking personality and reward dependence and self-directedness, cooperativeness, and self-transcendence before and after treatment with bupropion are significant.

In the bupropion group, the mean scores of NS, HA, RD, P, SD, CO, and ST were 8.20, 14.03, 8.40, 3.13, 8.00, 15.47, and 10.47, respectively, before treatment.

In the bupropion group, the mean scores of NS, HA, RD, P, SD, CO, and ST were 14.23, 13.60, 10.50, 3.57, 11.70, 16.57, and 11.43, respectively, after treatment (Table 4).

Table 4: Determining and comparison of the score of personality factors before and after treatment in the study group

gro	γup		
variable	group	n	mean
Novelty-seeking before drug use	bupropion	30	8.20
Novelty-seeking after drug use	bupropion	30	14.23
Harm avoidance before drug use	bupropion	30	14.03
Harm avoidance after drug use	bupropion	30	13.60
reward dependence before drug use	bupropion	30	8.40
reward dependence after drug use	bupropion	30	10.50
Persistence before drug use	bupropion	30	3.13
Persistence after drug use	bupropion	30	3.57
Self-directedness before drug use	bupropion	30	8.00
Self-directedness after drug use	bupropion	30	11.70
Cooperativeness before drug use	bupropion	30	15.47
Cooperativeness after drug use	bupropion	30	16.57
Self-transcendence before drug use	bupropion	30	10.47
Self-transcendence after drug use	bupropion	30	11.43

Out of 30 patients treated with bupropion, 18 were non-respondent to treatment and 12 were respondent to treatment. The appropriate response was considered to be a reduction of 50% or more in Beck score (Table 5).

Table 5: Response to treatment with bupropion drug*

Response to treatment	bupropion
NO	18
YES	12

^{*}The response to treatment was considered to be a reduction of 50% or more in Beck score $^{[15]}$

P-value of the correlation between factors NS, HA, RD, P, SD, ST before treatment and response to treatment with any of the drugs was not significant. However, the P-value correlation between CO and the response to treatment in the bupropion group was 0.026 and significant. The only correlation between the CO factor before treatment and the response to treatment was significant in the bupropion group, but other factors did not show a significant relationship with the response to treatment (Table 6).

Table 6: Relationship between factors before treatment and response to treatment in the bupropion group

	1 1 0 1
Personality factors	Respondent to treatment
	bupropion 12

NS.B	.926
HA.B	.540
RD.B	.882
P.B	.411
SD.B	.293
CO.B	.026
ST.B	.847

The correlation between the response to treatment with bupropion and temperament was -254 with a P-value of .175. In addition, the correlation between response to treatment and bupropion and character was -338 with P-value = 0.068 (Table 7).

Table 7: Correlation * between response to treatment and temperament and character

variable	Response to	treatment
-	bupropion	P-value
Temperament	254	.175
character	338	.068

^{*}The correlation number is between -1 and +1, in which the negative number indicates the inverse relationship and the positive number indicates the direct relationship between two factors.

Discussion and Conclusion

Personality disorder is one of the most common disorders and its control has always been considered serious clinically. Drug therapy is an effective therapeutic treatment for personality disorders. Psychiatric drugs also affect the personality traits through leaving an effect on neurotransmitters. The objective of this research was to evaluate the relationship between the use of drugs and personality factors, which could be helpful in the use of more effective drugs in the treatment of personality disorders. This research was conducted to evaluate the effect of the widely used drug in bupropion on personality factors. The mean age of the participants in the bupropion group was 38.57 years.

In this study, bupropion caused a significant change in NS, RD, ST, C, but it had no significant effect on HA and P. No similar study was found on the effect of bupropion on personality factors. In this study, bupropion led to an increase in NS, which is expected due to the dominant effect of bupropion on dopamine. In the study conducted by Lyoo et al. in 2003 in South Korea, it was found that the temperament more than character was a function of treatment [16]. In the present study, in the bupropion group, no significant relationship was found between response to treatment and temperament and character. Some studies have been conducted on personality dimensions as predictors of response to treatment with antidepressants in major depression, but they have not yielded consistent results. In the current study, significant correlation

was found only between the CO factor before the treatment and response to the treatment in the bupropion group.

Hence, based on the present study, CO before the treatment might predict response to treatment with bupropion. In the study conducted by Sato et al., CO and SD were predictors of response to antidepressants ^[17]. In the study conducted by Kampman, HA was associated with the response to treatment ^[11]. In the study conducted by Baeken, SD score predicted response to rTMS treatment in depressed patients ^[18]. In this study, only NS personality factor significantly changed in respondents and non-respondents, and other personality factors did not change significantly in the respondents and non-respondents. In the study conducted by Tomita, only SD factor changed significantly in non-respondents, but there was no significant difference between the respondents and non-respondents ^[10].

The limitation of the present study was the low number of patients. The higher number of patients and the comparison with healthy people might yield more useful results. Another limitation was that only the acute phase depression treatment was evaluated in this study and longer treatment might yield different results. In addition, the effects of other drugs such as benzodiazepine and anti-psychotics were not considered in the treatment of anxiety and insomnia, and the analysis of additional drugs might yield some important results. In this study, if the patient underwent anti-depressant treatment, she or he would be excluded from the study, unless 6 months passed since the completion of treatment. A number of studies have indicated the relationship between SSRIs and changes in personality factors of TCI in MDD patients. There are few reports on evaluation of TCI in patients with major depression disorder with SSRIs [7], and this is strength of this study. One another strength of this study was that other comorbidities were not diagnosed and not studied by clinical interviews. Finally, the results of this study revealed that personality factors change in patients with major depression disorder through bupropion treatment.

References

- Benjamin J Sadock, Virginia A Sadock, Pedro R, Kaplan
 Sadocks Comprehensive Textbookof Psychiatry,
 2009.
- Brown, S. L, Svrakic, D.M. Przybeck, TR. Cloninger, C. R. (1992). The Relationship of Personality to Mood and Anxiety states: A Dimensional Approach. Journal of psychiatric Research; 26,197-211.
- Kaviani and Pournasah. Validation and Normalization of Cloninger Temperament and Character Inventory (TCI) in Iranian population, 2005 (1990-2009).
- 4. Cloninger CR, Svrakic NM, Svrakic DM. Role of personality self-organization in development of mental

- order and disorder. Dev Psychopathol. 1997 Fall;9(4):881-906
- Peirson A. R (1), Heuchert JW, Thomala L, Berk M, Plein H, Cloninger CR" Relationship between serotonin and the temperament and character inventor".
 Psychiatry Res. 1999 Dec 13;89(1):29-37.
- Joyce PR, Mulder RT, Luty SE, McKenzie JM, Sullivan PF, Cloninger RC. Borderline personality disorder in major depression: symptomatology, temperament, character, differential drug response, and 6-month outcome. Compr Psychiatry. 2003 Jan-Feb;44(1):35-43.
- Gunasekara NS, Noble S, Benfield P. 1998. Paroxetine. An update of its pharmacology and therapeutic use in depression and a review of its use in other disorders. Drugs 55: 85–120.
- 8. Furukawa TA, Salanti G, Atkinson LZ, Leucht S, Ruhe HG, Turner EH, Chaimani A, Ogawa Y, Takeshima N, Hayasaka Y, Imai H, Shinohara K, Suganuma A, Watanabe N, Stockton S, Geddes JR, Cipriani A. Comparative efficacy and acceptability of first-generation and second-generation antidepressants in the acute treatment of major depression: protocol for a network meta-analysis. BMJ Open. 2016 Jul 8;6(7):e010919. doi: 10.1136/bmjopen-2015-010919.
- Patel K, Allen S, Haque MN, Angelescu I, Baumeister D, Tracy DK. Bupropion: a systematic review and meta-analysis of effectiveness as an antidepressant. Ther Adv Psychopharmacol. 2016 Apr;6(2):99-144. doi: 10.1177/2045125316629071. Epub 2016 Feb 18.
- 10. Tomita T, Kaneda A, Nakagami T, Kaneko S, Yasui-Furukori N. Changes in the Temperament and Character Inventory dimensions after paroxetine treatment in patients with major depressive disorder. Hum Psychopharmacol. 2015 Sep;30(5):334-40.

- Kampman O, Poutanen O, Illi A, Setälä-Soikkeli E, Viikki M, Nuolivirta T, Leinonen E.Temperament profiles, major depression, and response to treatment with SSRIs in psychiatric outpatients. Eur Psychiatry. 2012 May;27(4):245-9.
- 12. Joyce PR (1), Mulder RT, McKenzie JM, Luty SE, Cloninger CR. Atypical depression, atypical temperament and a differential antidepressant response to fluoxetine and nortriptyline. Depress Anxiety. 2004; 19(3):180-6.
- Hirano S (1), Sato T, Narita T, Kusunoki K, Ozaki N, Kimura S, Takahashi T, Sakado, K, Uehara T. Evaluating the state dependency of the Temperament and Character Inventory dimensions in patients with major depression. Department of Psychiatry, 2002; 470-1192.
- Cloninger CR, Svrakic DM, Przybeck TR. A psychobiological model of temperament and character.
 Arch Gen Psychiatry. 1993 Dec;50(12):975-90.
- Kheirkhah, F and Moghaddam, AA, Effect of ketamine on the treatment of patients with major depressive disorder. Journal of Babol University of Medical Sciences. June 2010.14-20.
- Lyoo IK, Yoon T, Kang DH, Kwon JS.Patterns of changes in temperament and character inventory scales in subjects with obsessive-compulsive disorder following a 4-month treatment. Acta Psychiatr Scand. 2003 Apr;107(4):298-304.
- 17. Sato T, Hirano S, Narita T, Kusunoki K, Kato J, Goto M, Sakado K, Uehara T. Temperament and character inventory dimensions as a predictor of response to antidepressant treatment in major depression. J Affect Disord. 1999 Dec;56(2-3):153-61.
- 18. Baeken C, Desmyter S, Duprat R, De Raedt R, Van Denabbeele D, Tandt H, Lemmens GM, Vervaet M, van Heeringen K .Self-directedness: an indicator for clinical response to the HF-rTMS treatment in refractory melancholic depression. Psychiatry Res. 2014 Dec 15;220(1-2):269-74.